EdgeMarket › What Lynx1 Capital Management Lp reported owning
What Lynx1 Capital Management Lp reported owning
As filed on Form 13F for the quarter ending 2026-03-31, up to 45 days after that date. Long-only US-listed equity — shorts, bonds, cash and non-US listings are not on the form, so this is one leg of the book, not the book.
Reported value
632.7MPositions
23Quarter
2026-03-31Shown below
23largest by value
| holding | value | % of book | shares | price | 1y |
|---|---|---|---|---|---|
| STOK Stoke Therapeutics, Inc. | 155.1M | 24.5% | 4.8M | 32.29 | +67.1% |
| GHRS GH Research PLC | 151.3M | 23.9% | 10.8M | 28.33 | +121.7% |
| CGEM Cullinan Therapeutics, Inc. | 127.4M | 20.1% | 9.0M | 21.68 | +190.2% |
| AGIO AGIOS PHARMACEUTICALS, INC. | 88.3M | 14.0% | 2.6M | 33.09 | -10.1% |
| DNLI Denali Therapeutics Inc. | 36.1M | 5.7% | 1.9M | 24.92 | +71.7% |
| CCCC C4 Therapeutics, Inc. | 18.4M | 2.9% | 7.0M | 4.00 | +53.8% |
| KRRO Korro Bio, Inc. | 17.4M | 2.8% | 1.5M | 13.18 | -31.6% |
| TCRX TScan Therapeutics, Inc. | 8.1M | 1.3% | 8.0M | 0.78 | -54.1% |
| XNCR Xencor Inc | 6.5M | 1.0% | 536.4K | 27.80 | +270.2% |
| DTIL PRECISION BIOSCIENCES INC | 5.4M | 0.9% | 985.1K | 8.85 | +89.9% |
| PASG Passage BIO, Inc. | 4.9M | 0.8% | 623.7K | 4.44 | -42.3% |
| NEUP Neuphoria Therapeutics Inc. | 3.6M | 0.6% | 875.3K | 3.91 | -43.7% |
| TRDA Entrada Therapeutics, Inc. | 2.7M | 0.4% | 211.7K | 7.57 | +42.6% |
| CGON CG Oncology, Inc. | 2.1M | 0.3% | 31.6K | 79.81 | +212.6% |
| IMTX Immatics N.V. | 2.1M | 0.3% | 217.0K | 8.93 | +59.5% |
| DSGN Design Therapeutics, Inc. | 1.3M | 0.2% | 119.5K | 14.99 | +212.9% |
| VYNE Yarrow Bioscience, Inc. | 973.1K | 0.2% | 1.6M | 28.56 | -57.4% |
| HOWL Werewolf Therapeutics, Inc. | 547.7K | 0.1% | 657.8K | 0.87 | -29.6% |
| IBIO iBio, Inc. | 129.3K | 0.0% | 68.1K | 1.43 | +88.2% |
| unmapped CUSIP 097702203 | 124.4K | 0.0% | 30.8K | — | — |
| PRQR ProQR Therapeutics N.V. | 110.9K | 0.0% | 68.5K | 2.34 | +9.3% |
| ABSI Absci Corp | 63.7K | 0.0% | 21.2K | 9.55 | +271.6% |
| TRAW Traws Pharma, Inc. | 27.6K | 0.0% | 15.1K | 0.53 | -60.2% |
A position that grew quarter on quarter may simply reflect a higher price: if the stock rose 40% and the manager did nothing, the reported value rose 40%. Reading that as accumulation is reading the price back to yourself. More on that →
The whole archive is one click away.
Screener, filings, insider flow, backtests and the AI — open without an account.
Free plan for good. Pro is $69.99/mo, or $4.99 for a 7-day trial. See the plans →